More about

Adalimumab

News
June 09, 2021
9 min watch
Save

VIDEO: Stelara, Humira safely, effectively treat CD

VIDEO: Stelara, Humira safely, effectively treat CD

Stelara and Humira demonstrated rapid onset of action and effectiveness in the treatment of patients with moderate to severe Crohn’s disease, Bruce Sands, MD, Icahn School of Medicine, told Healio Gastroenterology.

News
June 04, 2021
3 min read
Save

Upadacitinib maintains higher RA clinical response vs. adalimumab through 3 years

Upadacitinib maintains higher RA clinical response vs. adalimumab through 3 years

Upadacitinib continues to maintain higher levels of clinical response, compared with adalimumab, in patients with rheumatoid arthritis through 3 years, according to data presented at the EULAR 2021 Virtual Congress.

News
May 29, 2021
2 min watch
Save

VIDEO: Switching to bimekizumab improved psoriasis outcomes

VIDEO: Switching to bimekizumab improved psoriasis outcomes

Switching to bimekizumab resulted in better outcomes among certain patients with psoriasis who did not respond as well to adalimumab, according to results presented at AAD VMX 2021.

News
April 14, 2021
1 min read
Save

Drug retention not affected by adalimumab biosimilar switch

Patients with psoriasis who switched from Humira to adalimumab biosimilars for nonmedical reasons had similar drug retention as those who stayed on the originator, according to a study.

News
March 31, 2021
2 min read
Save

Higher-dose upadacitinib outperforms adalimumab in DMARD-refractory PsA

Higher-dose upadacitinib outperforms adalimumab in DMARD-refractory PsA

A daily 30 mg dose of upadacitinib — but not the 15 mg dose — is superior to adalimumab at improving the signs and symptoms of psoriatic arthritis among patients with inadequate response to non-biologic disease-modifying antirheumatic drugs.

News
March 04, 2021
3 min read
Save

Upadacitinib matches, exceeds adalimumab for improving patient-reported outcomes in RA

Upadacitinib matches, exceeds adalimumab for improving patient-reported outcomes in RA

Upadacitinib is equivalent or superior to adalimumab in improving patient-reported outcomes among those with rheumatoid arthritis and an inadequate response to methotrexate, according to data published in Rheumatology.

News
February 24, 2021
2 min read
Save

Adalimumab, CT-P17 biosimilar exhibit comparable safety, equivalent efficacy in RA

Adalimumab, CT-P17 biosimilar exhibit comparable safety, equivalent efficacy in RA

The adalimumab biosimilar CT-P17 demonstrates equivalent efficacy, and comparable safety and immunogenicity, to its reference product in patients with rheumatoid arthritis, according to data published in Arthritis Research & Therapy.

News
February 17, 2021
2 min read
Save

Filgotinib improves RA symptoms in patients with inadequate methotrexate response

Filgotinib improves RA symptoms in patients with inadequate methotrexate response

Filgotinib improves rheumatoid arthritis signs, symptoms and physician function, and inhibits radiographic progression, all while being well-tolerated in patients with an insufficient response to methotrexate, according to data.

News
December 15, 2020
2 min read
Save

Secukinumab not superior to adalimumab in patients with SpA who failed prior biologics

Secukinumab not superior to adalimumab in patients with SpA who failed prior biologics

Although secukinumab performs similarly to adalimumab in patients with spondyloarthritis who failed their first biological treatment, adalimumab proved superior in those who failed multiple biologics, according to data.

News
November 18, 2020
3 min read
Save

Herpes zoster more common with upadacitinib than adalimumab plus methotrexate in RA

Herpes zoster more common with upadacitinib than adalimumab plus methotrexate in RA

Among patients with rheumatoid arthritis, herpes zoster is more common in those treated with upadacitinib than with adalimumab plus methotrexate or with methotrexate alone, according to a speaker at ACR Convergence 2020.

View more